proceed protestor

Friday, May 3, 2013

Alyssa Milano: Our Bodies Are Not Made for Bikinis

"Our bodies are not made to look good in a string bikini!" the Mistresses star says.

Source: http://feeds.celebritybabies.com/~r/celebrity-babies/~3/KKIBkZAOkcc/

bank of america online banking Adairsville Ga ashley judd Alois Bell Donna Savattere deer antler spray Jason London

Thursday, May 2, 2013

Deal of the Day: SPE Top Pouch for Galaxy Note and Galaxy Note 2

The May 1 ShopAndroid.com Deal of the Day is the SPE Top Pouch for Galaxy Note and Galaxy Note 2. This pouch is a slim, genuine leather top case that fits your device perfectly for all-around protection. It features an extendable top flap which is used to secure your device inside the pouch. Easily slide the flap through the stitched opening on the front of the case and your smartphone is safe against drops and scratches. Comes in black, brown or white.

The SPE Top Pouch is available for just $14.00, 53% off today only. Backed by our 60-day return policy and fast shipping.

Never miss a deal. Sign up for Daily Deal alerts!

Source: http://feedproxy.google.com/~r/androidcentral/~3/fwiTt0e1RgY/story01.htm

Kwame Kilpatrick New pope 2013 good morning america earthquake california earthquake california douglas adams brandon knight

Allergan delays drug that would rival Regeneron's Eylea

By Esha Dey and Ransdell Pierson

(Reuters) - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.

Shares of Allergan, which makes wrinkle treatment Botox, fell 13.1 percent after the company said mid-stage trial results of Darpin did not warrant an immediate move into far larger late-stage trials. Regeneron shares closed up 10.3 percent.

If eventually approved, Darpin would also compete with Roche Holding AG's, Lucentis, to treat age-related macular degeneration - the most common form of blindness in the elderly.

Adnan Butt, an analyst with RBC Capital Markets, said Darpin's delay was "great news" for Regeneron. He noted that Wall Street had feared the Allergan drug might have a superior clinical profile to Eylea.

"This gives Eylea even more time to become entrenched as the drug to beat," Butt said.

He estimates that each year of Darpin delay will translate into an upside of about $15 to $20 for Regeneron shares, now trading at about $240.

Eylea, which was approved in November 2011, had sales last year of $838 million. Regeneron expects 2013 Eylea sales of $1.2 billion to $1.3 billion. Company officials would not comment on the setback for Allergan's drug.

Regeneron is expected to report first quarter results on Friday and could update its sales projections.

Allergan Chief Executive David Pyott said on a conference call that a mid-stage trial of Darpin showed some product differentiation over Lucentis, but did not support directly moving to late-stage development.

The company now plans to perform additional mid-stage trials to assess Darpin, which will delay its potential approval by one to two years.

"There was a rush to ascribe a lot of value to Darpin and our view is that this is still very much an unproven asset with limited data," Piper Jaffray analyst David Amsellem said.

"The earliest it could get to market now is likely 2019," Amsellem said. "If you couple that with the setback of the hair loss product, the late-stage pipeline for Allergan right now is really quite thin."

A mid-stage trial of Allergan's hair loss treatment Bimatoprost Scalp also failed to provide sufficient efficacy to proceed to a late-stage study, further weighing on company shares.

ROOM TO GROW

Regeneron in the past two years has vaulted seemingly out of nowhere to become one of the world's biggest biotechnology companies, thanks largely to Eylea.

The company has repeatedly raised its sales forecasts for the drug, which is injected into the eye, as it steadily steals market share from Lucentis.

Some specialty pharmacies also use Roche's Avastin cancer drug, which works the same way as Lucentis, but is far less expensive, when divided into smaller portions for treating macular degeneration.

Roche has said that dividing Avastin through a procedure not closely monitored by health regulators, called compounding, could compromise its sterility.

Regeneron Chief Executive Leonard Schleifer said in a recent interview that sales of Eylea could jump sharply if potential rivals stumble, or if U.S. regulators clamp down on the compounding of Avastin for eye use.

Moreover, he said some analysts believe Eylea sales could swell if it is approved for a new indication called diabetic macular edema now in late-stage trials. Lucentis is already approved for the condition.

"So Eylea is a growth story unto itself, with lots of room to still grow," Schleifer said.

Allergan on Wednesday also posted a higher-than-expected quarterly profit, helped by strong sales of Botox.

Net income for the first quarter fell to $12.5 million, or 4 cents per share, due to a loss of $259 million from discontinued operations. Profit was $229.8 million, or 74 cents per share, a year earlier.

Excluding special items, Allergan earned 98 cents per share. Analysts were expecting 96 cents, according to Thomson Reuters I/B/E/S.

Global company sales rose 8 percent to $1.46 billion, above Wall Street's average estimate of $1.44 billion.

Sales of Botox, which is also approved for treating migraine headaches, overactive bladder and underarm sweating, rose 15 percent to $457.9 million.

Allergan said it now expects 2013 adjusted earnings of $4.70 to $4.76 per share, compared with its prior outlook of $4.75 to $4.83 a share.

The company forecast a second-quarter profit of $1.18 to $1.20 per share, below analysts' average estimate of $1.22 a share. The new forecasts reflect the impact of its MAP Pharmaceuticals acquisition earlier this year.

Allergan shares fell $14.88 to $98.67 on the New York Stock Exchange, while Regeneron shares rose $25.15 to $237.29.

(Reporting by Esha Dey in Bangalore and Bill Berkrot in New York; Editing by Michele Gershberg, Sreejiraj Eluvangal, Carol Bishopric and Andre Grenon)

Source: http://news.yahoo.com/allergan-delays-drug-rival-regenerons-eylea-185323020.html

sylvia plath whitney houston autopsy results obama trayvon jim yong kim michael bush the host trailer whitney houston cause of death

Watch: Plan B Approved for Women 15 and Older

');
abcnws_fw_params = {siteSectionId: 'nws_vididx_health', siteSectionIdType: 0, siteSectionNetworkId: 168234, siteSectionFallbackId: 109527, customVisitor:'', keyValues:'pageType=videoindex'}; pc.fwSeg();pc.fwAppendKeyValues('show=');pc.getSWID();pc.subsectionOverride();
pc.affiliateCookie();
OB_FALLBACK = nextLoc;
function fw_config(){return abcnws_fw_params;}if (tq.videoOverrideContext != null) {
jsvideoViewEventProp16Value = tq.videoOverrideContext;
} else {
jsvideoViewEventProp16Value = "videoadtree|,videoadkeyword|ROSAdsOnly";
}
if (jsvideoViewEventProp16Value == "none") { jsvideoViewEventProp16Value = ""; }
jsvideoViewEventEvar20Value = jsvideoViewEventProp16Value;
currentURL = window.location.href;
closedCaptionActiveValue = true;
hdPluginActive = (currentURL.search('hdplugin=true') != -1)?true:false;

kdp_embed_default = {
doKdpEmbed : function() {
// Should only be changed if you are running Kaltura On Prem / Kaltura CE:
var service_url = "http://cdnapi.kaltura.com/";
// logic cascade for deciding which entry to load
var entry_id = this.getEntryIdFromUrl() || this.getEntryIdFromDataAttr() || this.fallback_entry;
var embedSrc = "http%3A%2F%2Fcdnapi.kaltura.com%2Findex.php%2Fextwidget%2FembedIframe%2Fentry_id%2F" + entry_id + "%2Fwidget_id%2F_" + kdp_embed_default.partner_id + "%2Fuiconf_id%2F" + kdp_embed_default.uiconf_id;
flashembed(this.placeholder_id,
{ // attributes and params:
id : "kaltura_player_default",
src : service_url + "/index.php/kwidget/wid/_" + kdp_embed_default.partner_id +
"/uiconf_id/" + kdp_embed_default.uiconf_id + "/entry_id/" + entry_id,
height : 361,
width : 640,
bgcolor : "#eeeeee",
allowNetworking : "all",
version : [10,0],
expressInstall : "http://cdn.kaltura.org/apis/seo/expressinstall.swf",
wmode: "transparent"
},
{ // flashvars (double-quote the values)
externalInterfaceDisabled : "false",
jsInterfaceReadyFunc : "jsInterfaceReady",
contentType: "video",

//"restrictUserAgent.restrictedUserAgents": "GoogleTV",
referer : "http://abcnews.go.com/Health/video/plan-b-approved-women-15-older-19085574",
"omniture.videoViewEventEvar15Value" : "player|videoindex",
"omniture.videoViewEventProp18Value" : "player|videoindex",
"omniture.videoViewEventProp16Value" : jsvideoViewEventProp16Value,
"omniture.videoViewEventEvar20Value" : jsvideoViewEventEvar20Value,
"omniture.adStartEvar15Value" : "player|videoindex",
"omniture.adStartEvar20Value" : jsvideoViewEventEvar20Value,
"closedCaptionActive" : closedCaptionActiveValue,

noThumbnail: true,
"abcnews.displayEndCard":false,
"addThis.embedCodeLinks" : "%3Ca%20href%3D%22http%3A%2F%2Fabcnews.go.com%2Fus%2F%3Fcid%3D11_extvid1%22%3EUS%20News%3C%2Fa%3E%7C%3Ca%20href%3D%22http%3A%2F%2Fabcnews.go.com%2Fentertainment%2F%3Fcid%3D11_extvid2%22%3EEntertainment%20News%3C%2Fa%3E%7C%3Ca%20href%3D%22http%3A%2F%2Fabcnews.go.com%2Fvideo%2F%3Fcid%3D11_extvid3%22%3EMore%20ABC%20News%20Videos%3C%2Fa%3E",
"addThis.iframeTemplate" : "%3Ciframe%20id%3D%22%24playerId%24%22%20height%3D%22360%22%20width%3D%22640%22%20style%3D%22%24cssStyle%24%22%20src%3D%22"+embedSrc+"%22%3E%24noIFrameMessage%24%3C%2Fiframe%3E%20%3Cdiv%20style%3D%22text-align%3Aleft%3Bfont-size%3Ax-small%3Bmargin-top%3A0%3B%22%3E%3Ca%20href%3D%22http%3A%2F%2Fabcnews.go.com%2Fus%2F%3Fcid%3D11_extvid1%22%3EUS%20News%3C%2Fa%3E%7C%3Ca%20href%3D%22http%3A%2F%2Fabcnews.go.com%2Fentertainment%2F%3Fcid%3D11_extvid2%22%3EEntertainment%20News%3C%2Fa%3E%7C%3Ca%20href%3D%22http%3A%2F%2Fabcnews.go.com%2Fvideo%2F%3Fcid%3D11_extvid3%22%3EMore%20ABC%20News%20Videos%3C%2Fa%3E%3C%2Fdiv%3E",
"shareBtnControllerScreen.enabled" : "true",
"outbrainKalturaVideo.plugin": "true","outbrainKalturaVideo.isDebug": "true","outbrainKalturaVideo.relativeTo": "PlayerHolder","outbrainKalturaVideo.path": "http://widgets.outbrain.com/fl/outbrainKalturaVideo.swf","outbrainKalturaVideo.position": "lastChild","outbrainKalturaVideo.idx": "1","outbrainKalturaVideo.playerSrcId": "ABCNewsKaltura","outbrainKalturaVideo.widgetId": "VP1","outbrainKalturaVideo.displayWidget": "true","outbrainKalturaVideo.sendStats": "true",

//"video.stretchThumbnail":true,
//"volumeBar.initialValue":0.75,
//"volumeBar.forceInitialValue":true,
debugMode: true

}
)
},
onFail : function() {
alert("FLASH EMBEDDING FAILED");
},
getEntryIdFromUrl : function() {
if(location.hash.indexOf(kdp_embed_default.url_param_name) != -1) {
// get the entry id from the url document fragment (aka hash):
return location.hash.split("#")[1].substring((kdp_embed_default.url_param_name.length+1));
}
else if(location.search.indexOf(kdp_embed_default.url_param_name) != -1) {
// get the entry id from the url parameters (aka querystring):
return location.search.split("?")[1].substring((kdp_embed_default.url_param_name.length+1));
}
else {
// use the default video defined in "fallback_entry" below:
// return kdp_embed_default.fallback_entry;
return false;
}
},
getEntryIdFromDataAttr : function() {
var data_attr_val = document.getElementById(this.placeholder_id).getAttribute("data-entryid");
if(data_attr_val && !(data_attr_val

Source: http://abcnews.go.com/Health/video/plan-b-approved-women-15-older-19085574

miranda lambert george strait Trey Burke Peyton Siva Hunter Hayes rick warren Final Four 2013

The conman and all-around terrible human being who sold fake bomb detectors to Iraq is getting 10 ye

The conman and all-around terrible human being who sold fake bomb detectors to Iraq is getting 10 years in jail, the maximum sentence that the judge could give. Good.

Amusement rides in U.S. injure 4,400 kids a year: Injuries higher on 'fixed' rides

May 1, 2013 ? A new study by researchers in the Center for Injury Research and Policy of The Research Institute at Nationwide Children's Hospital examined injuries to children related to amusement rides, which included rides at amusement parks (fixed-site rides), rides at fairs and festivals (mobile rides) and rides found at local malls, stores, restaurants or arcades (mall rides).

Researchers found that from 1990 to 2010, 92,885 children under the age of 18 years were treated in United States emergency departments for amusement ride-related injuries for an average of 4,423 injuries each year. More than 70 percent of the injuries occurred during the warm summer months of May through September -- equating to more than 20 injuries a day during these months.

The study, available online May 1, 2013 and in the May print issue of Clinical Pediatrics, found that the head and neck region was the most frequently injured (28 percent), followed by the arms (24 percent), face (18 percent) and legs (17 percent). Soft tissue injuries (29 percent) were the most common injury type followed by strains and sprains (21 percent), cuts (20 percent) and broken bones (10 percent). The overall percentage of injuries requiring hospitalization or observation was low, suggesting that serious injuries are relatively rare. However, during the summer months, May -- September, there is an amusement ride-related injury that is serious enough to require hospitalization once every three days on average.

Injuries were most likely to be sustained as the result of a fall (32 percent), or by either hitting a part of a body on a ride or being hit by something while riding (18 percent). Nearly one-third (33 percent) of injuries occurred on a fixed-site ride, followed by mobile rides (29 percent) and "mall" rides (12 percent).

"Although the U.S. Consumer Product Safety Commission has jurisdiction over mobile rides, regulation of fixed-site rides is currently left to state or local governments leading to a fragmented system," said the study's senior author Gary Smith, MD, DrPH, director of the Center for Injury Research and Policy of Nationwide Children's Hospital. "A coordinated national system would help us prevent amusement ride-related injuries through better injury surveillance and more consistent enforcement of standards."

The study also found that injuries associated with "mall rides" differed from fixed-site and mobile rides. They were more likely to be head/neck or face injuries, concussions/closed head injuries or cuts than were injuries associated with fixed site or mobile rides. Almost three-fourths of the "mall ride" injuries occurred when a child fell in, on, off or against the ride. These types of rides may be placed over hard surfaces and may not have child restraints, which contributes to the injury risk.

"Injuries from smaller amusement rides located in malls, stores, restaurants and arcades are typically given less attention by legal and public health professionals than injuries from larger amusement park rides, yet our study showed that in the U.S. a child is treated in an emergency department, on average, every day for an injury from an amusement ride located in a mall, store, restaurant or arcade," said Dr. Smith, who is also a professor of pediatrics at The Ohio State University College of Medicine. "We need to raise awareness of this issue and determine the best way to prevent injuries from these types of rides."

Some tips for keeping safe on amusement rides include:

Always follow all posted height, age, weight and health restrictions.
Make sure to follow any special seating order and/or loading instructions.
Always use safety equipment such as seat belts and safety bars.
Keep your hands and feet inside the ride at all times.
Know your child. If you don't think he/she will be able to follow the rules, keep him/her off the ride.
Trust your instincts. If you are worried about the safety of the ride, choose a different activity.
Avoid "mall rides" if they are over a hard, unpadded surface or if they don't have a child restraint such as a seat belt.

This is the first study to describe national rates of pediatric injury involving amusement rides treated in U.S. emergency departments. Data for this study were obtained from the National Electronic Injury Surveillance System (NEISS), which is operated by the U.S. Consumer Product Safety Commission. The NEISS provides information on consumer product-related and sports and recreation-related injuries treated in hospital emergency departments across the country.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Nationwide Children's Hospital, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Meghan C. Thompson, Thiphalak Chounthirath, Gary A. Smith,. US Pediatric Injuries Involving Amusement Rides, 1990-2010. Clinical Pediatrics, 2013 DOI: 10.1177/0009922813476341

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/top_health/~3/ClGEinQGMHA/130501091843.htm

hbo luck unc asheville stephen jackson marchmadness mike d antoni nba trade rumors desean jackson

Janos Starker dies: Leaves legacy as Grammy-winning cellist (+video)

Janos Starker dies: A renowned cellist, Janos Starker survived a Nazi concentration camp and became a world-class musician and teacher.

By Staff,?Associated Press / April 30, 2013

Janos Starker playing Bach: C Major Suite, during a 1989 recital in Tokyo, Japan.

Grammy Award-winning cellist Janos Starker has died after months of declining health. He was 88.

Skip to next paragraph

' + google_ads[0].line2 + '
' + google_ads[0].line3 + '

'; } else if (google_ads.length > 1) { ad_unit += ''; } } document.getElementById("ad_unit").innerHTML += ad_unit; google_adnum += google_ads.length; return; } var google_adnum = 0; google_ad_client = "pub-6743622525202572"; google_ad_output = 'js'; google_max_num_ads = '1'; google_feedback = "on"; google_ad_type = "text"; google_adtest = "on"; google_image_size = '230x105'; google_skip = '0'; // -->

Alain Barker, a spokesman for the Jacobs School of Music at Indiana University, said Starker died Sunday at his Bloomington home in the presence of family members.

Starker won a 1997 Grammy Award for best instrumental solo performance for a recording of Bach cello suites.

Starker made his professional debut at 14. He immigrated to the U.S. in 1948 and played for the Dallas Symphony, Metropolitan Opera Orchestra and Chicago Symphony before joining Indiana University in 1958.

In an NPR rememberance, Starker said teaching was his calling.

"I've been caught confessing that basically I was born to be a teacher," he said. "People question the validity of it, because I played all those 3, 4, 5,000 concerts in my life. But the fact is, I think I was put on earth to be a teacher."

The New York Times wrote of Starker: "The chief hallmark of his playing was a conspicuous lack of schmaltz. Effusive sentiment is an inherent risk of the cello, with its thundering sonorities and timbre so like the human voice. He also shunned the dramatic head tossing and body swaying to which many cellists incline.... Unlike many acclaimed string players, Mr. Starker used a lean, judicious vibrato ? the minute, rapid variations in pitch by the left hand that can enrich a note?s sound but can also border on the histrionic. Excessive vibrato, he said, was like ?a woman smearing her whole face with lipstick.?

He was born to Jewish parents in Budapest on July 5, 1924, and spent three months in Nazi concentration camps.

Survivors include his wife, Rae, and two daughters.

Source: http://rss.csmonitor.com/~r/feeds/csm/~3/GohZfO90GPI/Janos-Starker-dies-Leaves-legacy-as-Grammy-winning-cellist-video

aaron rodgers Lane Johnson Barkevious Mingo nfl draft 2013 NFL draft NFL.com Rebecca Martinson